Drug intelligence / Profile preview

bms-986166 + itraconazole

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986166 + itraconazole is a combination of BMS-986166, an oral small molecule prodrug that acts as a selective sphingosine 1-phosphate receptor 1 (S1P1) modulator, and itraconazole, an antifungal agent that is a known strong inhibitor of cytochrome P450 3A4 (CYP3A4). BMS-986166 is designed to modulate immune responses by inhibiting the egress of lymphocytes from lymphoid organs, with primary development focused on autoimmune and inflammatory diseases. The use of itraconazole in combination is primarily pharmacokinetic, serving as a CYP3A4 inhibitor to assess the impact of CYP inhibition on BMS-986166’s exposure, not as a therapeutic for a clinical indication in combination.

Targets

CYP3A4 (Cytochrome P450 3A4)EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on bms-986166 + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bms-986166 + itraconazole.

Explore the full profile